Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday

MT NewswiresOct 11 09:24 ET

Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study

MT NewswiresOct 11 07:41 ET

Express News | Sagimet Biosciences Inc - Denifanstat Shows Significant Improvements in Mash Resolution and Fibrosis

ReutersOct 11 07:00 ET

Sagimet Biosciences Announces Publication of Results From Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

GlobeNewswireOct 11 07:00 ET

Express News | Sagimet Biosciences Announces Publication of Results From Phase 2B Fascinate-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 Mash in the Lancet Gastroenterology & Hepatology

ReutersOct 11 07:00 ET

Sagimet Biosciences' Denifanstat Receives Buy Rating on FDA's BTD and Promising Trial Results

TipRanksOct 4 02:39 ET · Ratings